IM
$29.10
+0.72
(+2.54%)
As of Oct 22, 2026, 9:30 PM EDT · cached
Price history
Immunovant Inc (IMVT) is trading up at $29.10 (+2.54%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Immunovant Inc net income history (FY2019–FY2026)
Net income
| FY2019Mar 2019 | FY2020Mar 2020 | FY2021Mar 2021 | FY2022Mar 2022 | FY2023Mar 2023 | FY2024Mar 2024 | FY2025Mar 2025 | FY2026Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Net income | −$28.6M | −$66.4M | −$107.4M | −$156.7M | −$211.0M | −$259.3M | −$413.8M | −$505.6M |
| EPS (diluted) | −$1.29 | −$1.54 | −$1.22 | −$1.43 | −$1.71 | −$1.88 | −$2.73 | −$2.77 |
| Balance sheet | ||||||||
| Cash and equivalents | $6.99M | $100.6M | $400.1M | $493.8M | $376.5M | $635.4M | $714.0M | $902.1M |
| Total assets | $13.8M | $109.4M | $412.5M | $515.6M | $405.8M | $666.4M | $776.2M | $957.0M |
| Total liabilities | $6.49M | $15.3M | $21.0M | $45.7M | $43.3M | $48.6M | $68.8M | $104.4M |
| Shareholders' equity | $7.34M | $94.1M | $391.5M | $469.8M | $362.5M | $617.8M | $707.4M | $852.6M |
| Cash flow | ||||||||
| Operating cash flow | −$28.5M | −$53.4M | −$83.3M | −$106.1M | −$188.2M | −$214.2M | −$375.9M | −$407.3M |
| Capital expenditure | $52.0K | $31.0K | $210.0K | $254.0K | $197.0K | $360.0K | $759.0K | $8.00K |
| Free cash flow | −$28.6M | −$53.4M | −$83.5M | −$106.4M | −$188.4M | −$214.6M | −$376.6M | −$407.3M |
Net income
| Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25†Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26†Mar 2026 | Q1 FY27Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Net income | −$109.1M | −$111.1M | −$106.4M | −$120.6M | −$126.5M | −$110.6M | −$147.9M | −$153.2M |
| EPS (diluted) | −$0.74 | −$0.76 | −$0.63 | −$0.71 | −$0.73 | −$0.61 | −$0.72 | −$0.75 |
| Balance sheet | ||||||||
| Cash and equivalents | $472.9M | $374.7M | $714.0M | $598.9M | $521.9M | $994.5M | $902.1M | $797.8M |
| Total assets | $515.7M | $420.9M | $776.2M | $661.4M | $583.0M | $1.05B | $957.0M | $852.5M |
| Total liabilities | $66.7M | $68.3M | $68.8M | $52.9M | $63.3M | $66.3M | $104.4M | $117.1M |
| Shareholders' equity | $449.1M | $352.6M | $707.4M | $608.5M | $519.7M | $986.1M | $852.6M | $735.4M |
| Cash flow | ||||||||
| Operating cash flow | −$88.6M | −$100.4M | −$110.6M | −$117.4M | −$102.5M | −$92.3M | −$95.1M | −$124.4M |
| Capital expenditure | $196.0K | $180.0K | $201.0K | $0 | $0 | $0 | $8.00K | — |
| Free cash flow | −$88.8M | −$100.6M | −$110.8M | −$117.4M | −$102.5M | −$92.3M | −$95.1M | — |
From Immunovant Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Immunovant Inc
- Headquarters
- Durham, North Carolina From SEC filings, Oct 2026
Recent News (4)
-
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Mo…
-
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fi…
-
Immunovant CTO Jay Stout sells $122,116 in shares
Immunovant CTO Jay Stout sells $122,116 in shares
-
Immunovant COO Melanie Gloria sells shares worth $71,846
Immunovant COO Melanie Gloria sells shares worth $71,846
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International